Literature DB >> 18632618

The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects.

Lidia Moserle1, Stefano Indraccolo, Margherita Ghisi, Chiara Frasson, Elena Fortunato, Silvana Canevari, Silvia Miotti, Valeria Tosello, Rita Zamarchi, Alberto Corradin, Sonia Minuzzo, Elisabetta Rossi, Giuseppe Basso, Alberto Amadori.   

Abstract

The side population (SP), recently identified in several normal tissues and in a variety of tumors based on its ability to extrude some fluorescent dyes, may comprise cells endowed with stem cell features. In this study, we investigated the presence of SP in epithelial ovarian cancer and found it in 9 of 27 primary tumor samples analyzed, as well as in 4 of 6 cultures from xenotransplants. SP cells from one xenograft bearing a large SP fraction were characterized in detail. SP cells had higher proliferation rates, were much less apoptotic compared with non-SP cells, and generated tumors more rapidly than non-SP cells. We also investigated the effects of IFN-alpha, a cytokine that has widely been used to treat solid tumors, on epithelial ovarian cancer cells and observed that IFN-alpha exerted marked antiproliferative and proapoptotic effects on primary cultures containing high numbers of SP cells. In vitro, IFN-alpha treatment invariably caused a dramatic reduction in SP size in tumor cell lines of different origins; moreover, IFN-alpha treatment of purified SP cells was associated with a distinctive change in their transcriptional profile. Gene therapy with human IFN-alpha resulted in regression of established tumors bearing a large SP fraction, which was not observed when tumors bearing low SP levels were treated. These findings could have relevant clinical implications because they imply that tumors bearing large SP numbers, albeit rare, could be sensitive to IFN-alpha treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632618     DOI: 10.1158/0008-5472.CAN-07-6341

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

Review 1.  New promising drug targets in cancer- and metastasis-initiating cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Drug Discov Today       Date:  2010-03-23       Impact factor: 7.851

Review 2.  Immunotherapy for ovarian cancer.

Authors:  Justin M Drerup; Yang Liu; Alvaro S Padron; Kruthi Murthy; Vincent Hurez; Bin Zhang; Tyler J Curiel
Journal:  Curr Treat Options Oncol       Date:  2015-01

3.  Intratunical Injection of Genetically Modified Adipose Tissue-Derived Stem Cells with Human Interferon α-2b for Treatment of Erectile Dysfunction in a Rat Model of Tunica Albugineal Fibrosis.

Authors:  Ahmet Gokce; Zakaria Y Abd Elmageed; George F Lasker; Mostafa Bouljihad; Stephen E Braun; Hogyoung Kim; Philip J Kadowitz; Asim B Abdel-Mageed; Suresh C Sikka; Wayne J Hellstrom
Journal:  J Sex Med       Date:  2015-06-10       Impact factor: 3.802

Review 4.  Interferons as inducers of apoptosis in malignant cells.

Authors:  Kevin P Kotredes; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

Review 5.  Ovarian cancer stem cells: are they real and why are they important?

Authors:  Monjri M Shah; Charles N Landen
Journal:  Gynecol Oncol       Date:  2013-12-07       Impact factor: 5.482

6.  TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.

Authors:  Ilana Chefetz; Ayesha B Alvero; Jennie C Holmberg; Noah Lebowitz; Vinicius Craveiro; Yang Yang-Hartwich; Gang Yin; Lisa Squillace; Marta Gurrea Soteras; Paulomi Aldo; Gil Mor
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

Review 7.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

8.  Tumor stem cells: A new approach for tumor therapy (Review).

Authors:  Min Meng; Xin-Han Zhao; Qian Ning; Lei Hou; Guo-Hong Xin; Li-Feng Liu
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

9.  Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.

Authors:  Rachel Eyre; Ian Harvey; Katherine Stemke-Hale; Thomas W J Lennard; Alison Tyson-Capper; Annette P Meeson
Journal:  Tumour Biol       Date:  2014-07-04

10.  CSNK1α1 mediates malignant plasma cell survival.

Authors:  Y Hu; W Song; D Cirstea; D Lu; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2014-06-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.